Aequus Pharmaceuticals (CVE:AQS) Stock Price Up 25%

Aequus Pharmaceuticals Inc. (CVE:AQSGet Free Report)’s share price rose 25% on Thursday . The stock traded as high as C$0.06 and last traded at C$0.05. Approximately 223,000 shares changed hands during mid-day trading, an increase of 109% from the average daily volume of 106,695 shares. The stock had previously closed at C$0.04.

Aequus Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 138.88, a current ratio of 0.09 and a quick ratio of 0.46. The stock has a market capitalization of C$7.29 million, a P/E ratio of -2.75 and a beta of 0.73. The company has a fifty day moving average of C$0.04 and a two-hundred day moving average of C$0.04.

Aequus Pharmaceuticals (CVE:AQSGet Free Report) last announced its quarterly earnings data on Tuesday, August 29th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$0.10 million during the quarter. Aequus Pharmaceuticals had a negative net margin of 259.67% and a negative return on equity of 1,569.60%. On average, equities analysts anticipate that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.

About Aequus Pharmaceuticals

(Get Free Report)

Aequus Pharmaceuticals Inc, a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product.

Featured Articles

Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with's FREE daily email newsletter.